Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer-Reference-Cited by-全球学者库

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Published:2018-11-22 Issue:21 Volume:379 Page:2040-2051
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Paz-Ares Luis¹,Luft Alexander¹,Vicente David¹,Tafreshi Ali¹,Gümüş Mahmut¹,Mazières Julien¹,Hermes Barbara¹,Çay Şenler Filiz¹,Csőszi Tibor¹,Fülöp Andrea¹,Rodríguez-Cid Jerónimo¹,Wilson Jonathan¹,Sugawara Shunichi¹,Kato Terufumi¹,Lee Ki Hyeong¹,Cheng Ying¹,Novello Silvia¹,Halmos Balazs¹,Li Xiaodong¹,Lubiniecki Gregory M.¹,Piperdi Bilal¹,Kowalski Dariusz M.¹

Affiliation:

1. From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre Hospitalier...

Funder

Merck

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1810865

Cited by 2522 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab;Lung Cancer;2024-03

2. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer;Frontiers in Pharmacology;2024-02-05

3. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database;Int. Journal of Clinical Pharmacology and Therapeutics;2024-02-01

4. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations;Translational Oncology;2024-02

5. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial;Science Bulletin;2024-02